| Assay ID | Title | Year | Journal | Article |
|---|
| AID475399 | Agonist activity at human GAL4-tagged PPARgamma chimeric receptor expressed in HEK cells by transactivation assay | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| (S)-3-(4-(2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-(piperazin-1-yl) propanoic acid compounds: synthesis and biological evaluation of dual PPARalpha/gamma agonists. |
| AID475398 | Agonist activity at human GAL4-tagged PPARalpha chimeric receptor expressed in HEK cells by transactivation assay | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| (S)-3-(4-(2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-(piperazin-1-yl) propanoic acid compounds: synthesis and biological evaluation of dual PPARalpha/gamma agonists. |
| AID1395959 | Selectivity ratio of EC50 for GAL4-fused human PPARalpha LBD to EC50 for GAL4-fused human PPARgamma LBD | 2018 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
| Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARα selective agonists: New leads for oculovascular conditions. |
| AID330491 | Agonist activity at human PPARalpha | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
| Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPARalpha. |
| AID330492 | Agonist activity at human PPARgamma | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
| Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPARalpha. |
| AID1395958 | Agonist activity at GAL4-fused human PPARgamma LBD | 2018 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
| Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARα selective agonists: New leads for oculovascular conditions. |
| AID238856 | Binding affinity for human peroxisome proliferator activated receptor alpha | 2004 | Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
| Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. |
| AID240313 | Effective concentration against human peroxisome proliferator activated receptor gamma in Gal4 transactivation assay | 2004 | Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
| Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. |
| AID240312 | Effective concentration against human peroxisome proliferator activated receptor alpha in Gal4 transactivation assay | 2004 | Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
| Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. |
| AID238857 | Binding affinity for human peroxisome proliferator activated receptor gamma | 2004 | Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
| Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. |
| AID1140788 | Agonist activity at human PPAR-alpha | 2014 | Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10
| Identification of the first potent, selective and bioavailable PPARα antagonist. |
| AID475400 | Agonist activity at human GAL4-tagged PPARdelta chimeric receptor expressed in HEK cells at 30 uM by transactivation assay | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| (S)-3-(4-(2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-(piperazin-1-yl) propanoic acid compounds: synthesis and biological evaluation of dual PPARalpha/gamma agonists. |
| AID1395957 | Agonist activity at GAL4-fused human PPARalpha LBD | 2018 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 28, Issue:16
| Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARα selective agonists: New leads for oculovascular conditions. |
| AID475401 | Growth inhibition of HLF by MTT assay | 2010 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
| (S)-3-(4-(2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-(piperazin-1-yl) propanoic acid compounds: synthesis and biological evaluation of dual PPARalpha/gamma agonists. |
| AID1346733 | Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors) | 2001 | Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 98, Issue:24
| Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. |
| AID1346800 | Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors) | 2004 | Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
| Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. |
| AID1346800 | Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors) | 2001 | Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 98, Issue:24
| Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. |
| AID1346733 | Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors) | 2004 | Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
| Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |